| 20-HETE | 20-Hydroxy-eicosatetraenoic acid |
| 4T1 | Triple negative metastatic murine breast cancer cell line |
| ALX/FPR2 | Lipoxin A4 receptor/formyl peptide receptor |
| AA | Arachidonic acid |
| AAT | Antiangiogenic therapy |
| AKT | Protein kinase B |
| AMPK | 5′ AMP-activated protein kinase |
| BC | Breast cancer |
| BM | Brain metastasis |
| BSO | Buthionine sulfoximine |
| BT-474 | Breast cancer luminal B subtype cell line |
| COX | Cyclooxygenase enzyme |
| CXCR4 | C-X-C chemokine receptor type 4 also known as fusion or CD184; |
| CYP | Cytochrome P450 |
| CYP4A | Cytochrome P450, family 4, subfamily A |
| CYP4F | Cytochrome P450, family 4, subfamily F |
| DHETs | Dihydroxy-eicosatrienoic acids |
| EES | Extravascular extracellular space |
| EETs | Epoxy-eicosatrienoic acids |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| sEH | Epoxide hydrolase |
| EPCs | Endothelial progenitor cells |
| ER | Estrogen receptor |
| ERK | Extracellular signal-regulated kinases |
| Fas | Fas ligand or CD95 ligand |
| FGF-2 | Basic fibroblast growth factor 2 |
| FLA-16 | Novel flavonoid |
| GBM | Glioblastoma |
| GBM811 | Glioblastoma-derived from patient |
| GL261 | Murine glioblastoma cell line |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GSH | Glutathione |
| GPx | Glutathione peroxidase |
| HER2 | Human epidermal growth factor receptor2 |
| HET0016 | N-hydroxy-N′-(4-butyl-2 methyl phenyl) formamidine |
| HF2303 | Glioblastoma-derived from patient |
| HIF-1α | Hypoxia-inducible factor 1 α |
| HO | Hepoxillin |
| HPβCD | 2-Hydroxypropyl β-cyclodextrin |
| HPETE | Hydroperoxy-eicosatetraenoic acid |
| HUVEC | Human umbilical vein endothelial cells |
| IL | Interleukin |
| IV | Intravenous |
| Ki67 | Proliferation marker |
| Ktrans | Forward permeability transfer constant |
| LOX | Lipoxygenase |
| LT | Leukotriene |
| LX | Lipoxin |
| MAPK | Mitogen-Activated Protein Kinase |
| MCP-1 | Monocyte Chemoattractant Protein-1 |
| MDA-MB-231 | Triple negative metastatic human breast cancer cell line |
| MDSCs | Myeloid-derived suppressor cells |
| MMPs | Matrix metalloproteinases |
| MRI | Magnetic resonance imaging |
| MVD | Microvessel density |
| NADPH | Nicotinamide adenine dinucleotide phosphate |
| NFκB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| eNOS | Endothelial nitric oxide synthase |
| PDX | Patient-derived xenograft |
| PET | Polyethylene terephthalate |
| PG | Prostaglandin |
| PI3K | Phosphatidylinositol-3-kinases |
| PLA2 | Phospholipase A2 |
| PPARs | Peroxisome proliferator-activated receptors |
| PR | Progesterone receptor |
| ROS | Reactive oxygen species |
| SCF | Stem cell factor |
| SDF-1α | Stromal cell-derived factor 1 α |
| STAT1 | Signal transducer and activator of transcription 1 |
| T2DM | Type 2 diabetes mellitus |
| T47D | Breast cancer luminal A subtype cell line |
| TAMs | Tumor-associated macrophages |
| TGF-β | Transforming growth factor β 1 |
| Tie-2 | Transmembrane tyrosine-protein kinase receptor |
| TME | Tumor microenvironment |
| TMZ | Temozolomide |
| TNBC | Triple-negative breast cancer |
| TNFα | Tumor necrosis factor α |
| U251 | Human glioblastoma cell line |
| ve | extracellular space or interstitial volume |
| VE-cadherin | Vascular endothelial cadherin |
| VEGF | Vascular endothelial growth factor |
| VLA-4 | Very late antigen-4 |
| vp | Blood plasma pool |
| α-SMA | α-smooth muscle actin |